Karen A. Gelmon

← Back to University of British Columbia

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. Palbociclib and Letrozole in Advanced Breast Cancer

   2016 · 2,971 citations

2. Metastatic Behavior of Breast Cancer Subtypes

   2010 · 2,247 citations

3. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

   2016 · 2,033 citations

4. The clonal and mutational evolution spectrum of primary triple-negative breast cancers

   2012 · 1,965 citations

5. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

   2021 · 1,712 citations

6. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

   2007 · 1,507 citations

7. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

   2020 · 1,356 citations

8. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

   2019 · 1,320 citations

9. Regional Nodal Irradiation in Early-Stage Breast Cancer

   2015 · 1,294 citations

10. Breast Cancer Subtypes and the Risk of Local and Regional Relapse

    2010 · 1,243 citations

11. Ki67 in breast cancer: prognostic and predictive potential

    2010 · 1,207 citations

12. Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial

    2007 · 1,179 citations

13. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

    2018 · 1,171 citations

14. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

    2011 · 1,117 citations

15. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

    2010 · 1,116 citations

16. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

    2009 · 1,069 citations

17. Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial

    2005 · 1,027 citations

18. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    2023 · 1,008 citations

19. Exemestane for Breast-Cancer Prevention in Postmenopausal Women

    2011 · 973 citations

20. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

    2010 · 796 citations

21. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

    2014 · 786 citations

22. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

    2016 · 644 citations

23. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

    2010 · 643 citations

24. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

    2018 · 636 citations

25. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution

    2014 · 598 citations

← Return to the university profile